Sanofi and Translate Bio to jointly produce mRNA Covid-19 vaccine
Category: #health  | By Nikita Chaurasia  | Date: 2020-06-25 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Sanofi and Translate Bio to jointly produce mRNA Covid-19 vaccine

French multinational pharmaceutical company Sanofi S.A. is reportedly expanding its collaboration with Translate Bio, a U.S-based mRNA therapeutics company to develop a wide range of messenger ribonucleic acid (mRNA) vaccines against Covid-19. The financial valuation of the new enhanced partnership deal is reported to be USD 2.8 billion.

For those uninitiated, Translate Bio is a leading company that offers mRNA technology which enables human cells to produce specific proteins which help in boosting the immunity system against specific diseases.

Sources close to the matter stated that the deal allows Sanofi to strengthen its position in the race to discover effective and safe vaccine for coronavirus, which has killed around 472,000 people across the globe.

The deal will also provide Sanofi up to 7.2 percent of the Translate Bio’s business as well as exclusive global rights to produce, manufacture, and distribute the vaccine, sources claimed.

Sanofi mentioned in a comment that it expects its mRNA-based Covid-19 vaccine to enter clinical trails by the end of the year, and if successful, will acquire regulatory approval by next year.

Translate Bio will evidently secure an upfront payment of around USD 425 million, which comprises of USD 300 million in cash and stocks worth USD 125 million, sources claimed.

The Massachusetts-based biotech company is also apparently eligible to avail the benefits from further potential milestones as well as other payments of around USD 1.9 billion. According to reliable sources, the deal will make Sanofi the fourth-largest shareholder of Translate Bio.

The two companies are also developing Covid-19 vaccine with Britain’s GlaxoSmithKline, which is expected to receive approval by first half of next year, cite sources.

In other news, China-based Chongqing Zhifei Biological Products publicized that it would soon begin its human trials for recently approved Covid-19 vaccine.

Source Credits –

https://www.straitstimes.com/world/europe/sanofi-in-28b-deal-with-us-firm-to-make-vaccines-amid-virus-fight

https://medcitynews.com/2020/06/sanofi-translate-bio-ramp-up-partnership-on-vaccines-translate-to-receive-up-to-2-3b/?rf=1

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...